EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

The HGF/MET Axis in Advanced Prostate Cancer: From Context-Dependent Biology to Biomarker-Driven Therapeutic Strategies

Filippos Koinis iD, Maria Smaragdi Vlachou, Georgios Nintos, Georgios Christodoulopoulos, Emmanouil Panagiotidis iD, Ioannis Eleftheropoulos, Galatea Kallergi iD, Michail Samarinas, Athanasios Kotsakis iD

Cancers · 02.05.2026 · 18 (9) · 1463

DOI: 10.3390/cancers18091463 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 02.05.2026. Verfasst von Filippos Koinis und 8 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Oncology, Faculty of Medicine, School of Health Sciences, University of Thessaly, GR-41110 Larissa, Greece. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 90 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Research Grants of the University of Thessaly.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Advanced prostate cancer (PCa) evolves through adaptive mechanisms that sustain tumor growth despite the suppression of androgen receptor (AR) signaling. Accumulating evidence identifies activation of the hepatocyte growth factor (HGF)/MET pathway as a potential driver of PCa progression in advanced disease states characterized by AR-independence and therapeutic resistance. We review the biological and clinical evidence supporting MET as a context-dependent therapeutic target and discuss its implications for patient selection and combination strategies.

Methods

A comprehensive narrative review of preclinical, translational, and clinical studies evaluating MET-directed therapies for PCa was performed.

Results

Aberrant activation of the HGF–MET axis is frequently driven by autonomous paracrine and autocrine loops that sustain pathway activation during disease progression. MET overexpression is associated with adverse pathological features, increased tumor aggressiveness, bone metastasis, lineage plasticity, and resistance to AR-targeted treatments. Preclinical studies have demonstrated that AR suppression, tumor hypoxia and tumor–microenvironment interactions promote MET upregulation, supporting AR-independent growth and epithelial-to-mesenchymal transition. Clinical trials of MET inhibitors have shown modest activity as monotherapies, with the most consistent biological effects observed in bone-dominant disease. Recent studies indicate greater therapeutic potential when MET inhibition is incorporated into rational combination strategies targeting complementary molecular pathways. Emerging data further indicate that MET activation characterizes a biologically aggressive, AR-low or neuroendocrine-like disease state. These findings support a transition from empiric use of MET inhibitors toward precision, context-driven therapeutic development.

Conclusions

MET is not a universal therapeutic target but defines a clinically relevant subset of aggressive, AR-indifferent PCa. Future development should focus on biomarker-guided patient selection and rational combination strategies. Integration of molecular profiling, imaging, and liquid biopsy approaches will be essential to identify patients most likely to benefit from MET-directed interventions.

Schlagwörter

Stichwörter der Autor:innen

AR-indifferentMET pathwayaggressive prostate cancerbiomarkerscabozantinibprecision medicineprostate cancertargeted treatment

Autor:innen und Institutionen

  • Laboratory of Oncology, Faculty of Medicine, School of Health Sciences, University of Thessaly, GR-41110 Larissa, Greece.
  • Department of Medical Oncology, University General Hospital of Larissa, 41110 Larissa, Greece.
  • Department of Nuclear Medicine, Faculty of Medicine, School of Health Sciences, University of Thessaly, 41110 Larissa, Greece.
  • Department of Urology, General Hospital Asklipieion of Voula, 16673 Voula, Greece.
  • Laboratory of Biochemistry and Metastatic Signaling, Department of Biology, University of Patras, 26504 Patras, Greece.
  • 2nd Department of Urology, Medical School, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece.

ORCID-Profile: Filippos Koinis, Emmanouil Panagiotidis, Galatea Kallergi, Athanasios Kotsakis

Förderung

  • Research Grants of the University of Thessaly

Zitieren

APA

Koinis, F., Vlachou, M. S., Nintos, G., Christodoulopoulos, G., Panagiotidis, E., Eleftheropoulos, I., Kallergi, G., Samarinas, M., & Kotsakis, A. (2026). The HGF/MET Axis in Advanced Prostate Cancer: From Context-Dependent Biology to Biomarker-Driven Therapeutic Strategies. Cancers, 18(9), 1463. https://doi.org/10.3390/cancers18091463

Vancouver

Koinis F, Vlachou MS, Nintos G, Christodoulopoulos G, Panagiotidis E, Eleftheropoulos I, et al. The HGF/MET Axis in Advanced Prostate Cancer: From Context-Dependent Biology to Biomarker-Driven Therapeutic Strategies. Cancers. 2026;18(9):1463. doi:10.3390/cancers18091463

BibTeX
@article{Koinis2026,
  author = {Koinis, Filippos and Vlachou, Maria Smaragdi and Nintos, Georgios and Christodoulopoulos, Georgios and Panagiotidis, Emmanouil and Eleftheropoulos, Ioannis and Kallergi, Galatea and Samarinas, Michail and Kotsakis, Athanasios},
  title = {The HGF/MET Axis in Advanced Prostate Cancer: From Context-Dependent Biology to Biomarker-Driven Therapeutic Strategies},
  journal = {Cancers},
  year = {2026},
  volume = {18},
  number = {9},
  pages = {1463},
  doi = {10.3390/cancers18091463}
}
Kostenlos starten →